

TUESDAY 21ST SEPTEMBER

12.45-13.10 VIRTUAL EXHIBITION



“Life beyond the coronavirus pandemic” Lessons learned to take the transplant service forwards	
13.10-13.15	Introduction and Welcome by Dr Varuna Aluvihare (Chair BLTG)
13.17 – 13.32	A collaborative approach to benefit patients - “Collaboration during the pandemic had a positive outcome.” Prof Doug Thorburn (<i>Hepatologist, Royal Free</i>) & Ms Rhiannon Taylor (<i>Senior Statistician, NHSBT</i>)
13.34-13.54	Overcoming barriers to referral - “The factor that most influenced a unit’s ability to assess for transplantation was a lack of referrals from the catchment area.” Dr Richard Aspinall (<i>Hepatologist, Portsmouth</i>) & Dr Varuna Aluvihare (<i>Hepatologist, Kings</i>)
13:54-14:00	BREAK
14.00-14.20	Standardising the transplant assessment process – to list or not to list? - “Prioritising when considering the risk benefit ratio of transplantation differed between units; and the potential movement of patients between transplant units highlighted our need to standardise.” Panel discussion – Metabolic syndrome/frailty Case presented by: Chiemelie Ngonadi (SPR, Birmingham) Panel: Dr Matt Armstrong (<i>Hepatologist, Birmingham</i>); Dr Rebecca Jones (<i>Hepatologist, Leeds</i>); Dr John Klinck (<i>Anaesthetist, Cambridge</i>); Dr John Isaac (<i>Anaesthetist, Birmingham</i>)
14.22-14.42	Panel discussion – Alcohol Case presented by: Dr Aaron Wetten (<i>Specialist Registrar and Clinical Research Fellow in Hepatology, Newcastle</i>) Panel: Dr Steve Masson (<i>Hepatologist, Newcastle</i>); Dr Andrew Bathgate (<i>Hepatologist, Edinburgh</i>); Dr Mike Allison (<i>Hepatologist, Cambridge</i>); Mr Kerry Webb (<i>Nurse Consultant, Birmingham</i>)
14.44-14.59	Best transplant abstracts P064 (79) - Genetic evaluation of patients listed for liver transplantation with cryptogenic cirrhosis Dr Jeremy Nayagam
14.59-15.14	P046 (55) - Liver re-transplantation in adults; a single UK centre experience (2009-2020) Dr James Morgan
15.14-15.40	BREAK & VIRTUAL EXHIBITION

This meeting is supported by way of purchase of sponsorship or exhibition space by the companies listed in the exhibition area and is limited to meeting the cost of the scientific meeting with no input to the programme

15.40-16.00	<p>Ensuring the resources are in place</p> <ul style="list-style-type: none"> - “Transplant staff were not seen as a priority - with widespread redeployment.” <p>Panel discussion – Work force planning</p> <p>Panel: Dr Andrew Holt (<i>Hepatologist, Birmingham</i>); Prof Brian Davidson (<i>Surgeon, Royal Free</i>); Mr Derek Manas (<i>Surgeon, Newcastle</i>); Mr Aimen Amer (<i>Surgeon</i>); Dr Agimol Pradeep (<i>Liver transplant co-ordinator, Kings</i>); Audrey Dillon (<i>Hepatologist</i>); Sarah Watson (<i>Commissioning</i>)</p>
16.02-16.22	<p>National service evaluation: Current challenges in liver ITU</p> <p>Dr Brian Hogan (<i>Hepatologist and Intensivist, Kings</i>)</p>
16:22-16:25	BREAK
16.25-16.55	<p>Williams Calne Lecture: Expanding the donor pool for liver transplantation</p> <p>Prof Robert J Porte (<i>University Medical Center Groningen, The Netherlands</i>)</p>
16.55-17.00	<p>Final comments and close by Dr Varuna Aluvihare</p>



WEDNESDAY 22ND SEPTEMBER

- 11.30-12.15 – Industry symposium – Grifols UK Ltd
Why is Albumin more than a fluid?
Prof Rajiv Jalan (UCL)
Chair: Dr Duncan Stacey
- 11.30-12.15 – Industry symposium – Gilead
Gilead Organised and Funded HDV Symposium: Understanding the
key challenges in HDV
Dr Patrick Kennedy, Dr Kosh Agarwal & Dr Ahmed Elsharkawy
Chair: Dr Ahmed Elsharkawy

12.15-12.50 **VIRTUAL EXHIBITION**

12.50-12.58 Welcome by BASL President

Session Chairs – Prof Guru Aithal and Dr Victoria Snowden

Technology in Translation symposium

- 13.00-13.20 Digital technology for community management of fatty liver
Prof Suzanne Norris
- 13.20-13.40 Faecal microbiota transplantation for chronic liver disease
Prof Debbie Shawcross
- 13.40-13.55 Raman spectroscopy for liver biology and pathology
Colin Campbell
- 13.55-14.15 Panel Discussion
- 14.15-14.20 **BREAK**
- 14.20-14.50 **Dame Sheila Sherlock Research Award**
Harnessing peripheral & intrahepatic immune responses to optimise
treatment strategies for chronic hepatitis B
Dr Upkar Gill

14.50-15.25 **BREAK & VIRTUAL EXHIBITION**

Session Chairs – Prof Helen Reeves and Dr Ian Rowe

- Free Papers
- 15.25-15.35 O03 (38) - A novel nurse-led early post-discharge clinic is associated
with fewer readmissions and lower mortality following an index
hospitalisation with decompensated cirrhosis
Dr Benjamin Giles
- 15.35-15.45 O04 (42) - Serum nuclear magnetic resonance metabolomic signature
can discriminate immunoglobulin G4-related sclerosing cholangitis
and primary sclerosing cholangitis
Dr Emmanuel Selvaraj



- 15.45-15.55 O06 (66) - Aminobisphosphonates enhance liver-resident gamma delta T cells for efficient targeting of hepatocellular carcinoma
Dr Nekisa Zakeri
- 15.55-16.05 O08 (84) - Dietary factors underlying non-alcoholic fatty liver disease (NAFLD) and its severity: a large, population-based, case-control study
Amina Al-Awadi
- 16.05-16.15 **BREAK**
- 16.15-16.45 **Ralph Wright Lecture**
Curing Chronic Hepatitis B
Prof Geoff Dusheiko
- 16.45-16.50 Day Closing remarks and close



THURSDAY 23RD SEPTEMBER

- 10.30-11.15 – Industry symposium – Shionogi
The Platelet Plan: Paradigms, Pathways and Perspectives
Vanessa Hebditch, Valerie Ross & Prof James Neuberger
Chair: Prof Stephen Ryder
- 10.30-11.15 – Industry symposium – Intercept
PBC: Longer-term Considerations
Prof Dave Jones
- 11.30-12.15 – Industry symposium – Norgine
Optimising care and reducing hospital re-admissions for people with
chronic hepatic encephalopathy
Dr Richard Aspinall
Chair: Dr Mark Hudson

12.15-12.50 VIRTUAL EXHIBITION

Session Chairs – Dr Oliver Tavabie and Prof Salim Khakoo Rapid Updates – Part 1

- 13.00-13.10 ALF – Dr Will Bernal
13.10-13.20 Alcohol-related Liver – Dr Ashwin Dhandra
13.20-13.30 CCA-UK - Dr Shahid Khan
13.30-13.40 End of Life – Dr Ben Hudson
13.40-13.50 HBV – Dr Patrick Kennedy
13.50-14.00 HCC-UK – Dr Richard Hubner

14.00-14.05 BREAK

Rapid Updates – Part 2

- 14.05-14.15 Autoimmune Liver – Dr Palak Trivedi
14.15-14.25 NAFLD – Dr William Alazawi
14.25-14.35 Portal Hypertension – Prof Dhiraj Tripathi
14.35-14.45 Acute on Chronic Liver Failure – Prof Rajiv Jalan
14.45-14.55 Pathology – Dr Tim Kendall
14.55-15.05 Paediatrics – Dr Jane Hartley

15.05-15.35 BREAK & VIRTUAL EXHIBITION

Session Chairs – Dr James Ferguson and Dr Shilpa Chokshi

- 15.35-16.05 **Andy Burroughs Young Investigator Award**
From organoids to organs: a journey of clinical translation
Dr Fotios Sampaziotis



- 16.07-16.22 National Survey of Primary care pathways from liver disease
Vanessa Hebditch & Dr Helen Jarvis
- 16.24-16.59 **Introduction to BLT Lecture**
Pamela Healy OBE
British Liver Trust Lecture
The BASL Inclusiveness Project
Dr Rebecca Jones, Dr Jude Oben, Dr Ahmed Elsharkawy, Dr Saket Singhal and Dr Joanna Leithead
- 16.59-17.05 **BREAK**
- 17.05-17.20 UK Liver Alliance
Pamela Healy OBE & Prof Phil Newsome
- Free Papers
- 17.22-17.32 O09 (105) - A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent Carbalive (Yaq-001) in cirrhotic patients
Dr Jane Macnaughtan
- 17.32-17.42 O10 (112) - Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure; results of the first multicenter randomized trial (GRAFT study)
Dr Cornelius Engelmann
- 17.42-17.47 Day Closing remarks and close



FRIDAY 24TH SEPTEMBER

10.30-11.15 – Industry symposium – SIRTEx

12.15-12.45 **VIRTUAL EXHIBITION**

Session Chairs – Dr Tamir Rashid and Dr Bill Griffiths

Rare Disease Symposium

12.45-13.05 Antitrypsin deficiency related liver disease: Targets and treatments
Prof David Lomas, UCL

13.05-13.25 Wilson's disease: New Developments
Dr Mike Schilsky, Yale

13.25-13.45 Porphyria: Interventions
Dr Bruce Wang, UCSF

13.45-14.00 Panel Discussion

14.00-14.05 **BREAK**

14.05-14.50 BASL Annual Business Meeting

14.50-15.15 **BREAK & VIRTUAL EXHIBITION**

Session Chairs – Dr Rebecca Jones and Prof Michael Heneghan

Free Papers

15.15-15.25 O01 (4) - Genetic analysis and phenotypic correlation in ductal plate malformation
Dr Meha Bhuvu

15.25-15.35 O02 (21) - Deep sequencing of HCC endothelium reveals an active role in immunosuppression and highlights the ecto nucleotidase CD73 as a potential therapeutic target.
Dr Rosemary Faulkes

15.35-15.45 O05 (57) - Opportunities to intervene after early detection of alcohol related liver disease
Dr Tiwonge Jason Nyirenda

15.45-15.55 O07 (73) - FXR antagonists as new agents for COVID19
Teresa Brevini

15.55-16.00 **BREAK**

16.00-16.30 **Alex Mowat Lecture** - Progressive Familial Intrahepatic Cholestasis: Discovery to Disease modifying drugs
Dr William Balistreri, Cincinnati

16.30-16.35 Closing remarks and close

FRIDAY 24TH SEPTEMBER



09:30 – 09:40	Welcome and Introduction Michelle Clayton, BLNA Chair
09:40 - 09:57	Meet the new BLNA committee
09:57 – 10:42	<p>Decompensated ArLD Chairs - Rebecca West and Michelle Clayton Speakers: Dianne Backhouse, Liver CNS Hull Royal Infirmary & Liz Farrington, Liver Nurse Consultant, Royal Cornwall Hospital</p> <p>Introduction to the case study *Pathophysiology *Investigations Case study update *Management options Case study outcome</p>
10:42 – 10:50	BREAK
10:50 – 11:22	<p>Drug induced liver injury Chairs – Ricky Gellissen and Michelle Clayton Speaker: Catherine Wood, Virtual Liver CNS, Royal Cornwall Hospital</p>
11:22 – 12:02	<p>Nutrition in Liver Disease Chairs - Gemma Botterill and Michelle Clayton Speaker: Jennifer Towey, Specialist Dietitian, University Hospitals Birmingham</p>
12:02 – 12:10	<p>Delegate Feedback Michelle Clayton, BLNA Chair</p>
12:10 – 12:55	LUNCH
12:55 – 13:07	<p>Welcome Michelle Clayton, BLNA Chair</p>
13:07 – 13:22	<p>Oral presentations Chairs - Liz Farrington and Ricky Gellissen</p> <p>P004 (5) - Service evaluation of a patient centred pathway to support self management and weight loss for patients with non-alcoholic fatty liver disease Mary McCallum, Health Psychologist, NHS Grampian</p>
13:22 – 13:37	<p>P025 (29) - OSHI (Open Source Healing Initiative): An example of patient-led innovation in liver services Dianne Backhouse Liver CNS & James Hall patient representative, Hull</p>

This meeting is supported by way of purchase of sponsorship or exhibition space by the companies listed in the exhibition area and is limited to meeting the cost of the scientific meeting with no input to the programme

13:37 – 13:52	O03 (38) - A novel nurse-led early post-discharge clinic is associated with fewer readmissions and lower mortality following an index hospitalisation with decompensated cirrhosis Kirsty Fancey & Karen Gamble – Liver CNS's, Portsmouth
13:55 – 14:25	The impact of Covid- 19 on people with and at risk of liver disease Chairs - Liz Farrington and Rebecca West Speaker: Rebecca Blackwell, Liver CNS, Addenbrooke Hospital, Cambridge
14:25 – 14:35	BREAK
14:35 – 15:35	Wilson's disease Chairs - Michelle Clayton and Catherine Wood Introduction to the case study *What is Wilson's Disease? Speaker: Gemma Botterill, Viral Hepatitis CNS, Birmingham Case study update *Understanding Acute Liver Failure Speaker: Adam Riedlinger, Lecturer practitioner, Kings College Hospital, London Case study update *Transplant and beyond Speaker: Dawn Stevenson, Liver recipient transplant co-ordinator, St. James's University Hospital, Leeds
15:37 – 16:02	Update on Hepatitis B Chairs - Michelle Clayton and Ricky Gellissen Speaker: Kate Jack, Viral Hepatitis CNS, Nottingham
16:02 – 16:15	Evaluation Michelle Clayton, BLNA Chair
16:15	Meeting Close